"Neurofibromin 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein found most abundantly in the nervous system. Defects or deficiencies in this protein are associated with NEUROFIBROMATOSIS 1, Watson syndrome, and LEOPARD syndrome. Mutations in the gene (GENE, NEUROFIBROMATOSIS 1) affect two known functions: regulation of ras-GTPase and tumor suppression.
| Descriptor ID |
D025542
|
| MeSH Number(s) |
D12.644.360.325.150.500.460 D12.776.476.325.150.500.460 D12.776.624.776.610
|
| Concept/Terms |
Neurofibromin 1- Neurofibromin 1
- Neurofibromatosis Type 1 Protein
- NF1-GAP-Related Protein
- NF1 GAP Related Protein
- NF-1 Protein
- NF 1 Protein
- NF1 GRP
- NF1 Protein
- Neurofibromin
- Neurofibromatosis Type 1 Gene Product
|
Below are MeSH descriptors whose meaning is more general than "Neurofibromin 1".
Below are MeSH descriptors whose meaning is more specific than "Neurofibromin 1".
This graph shows the total number of publications written about "Neurofibromin 1" by people in this website by year, and whether "Neurofibromin 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 3 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 4 | 5 |
| 2019 | 3 | 1 | 4 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurofibromin 1" by people in Profiles.
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
-
Splicing is an alternate oncogenic pathway activation mechanism in glioma. Nat Commun. 2022 01 31; 13(1):588.
-
Coincidental Expression of Classic Hodgkin Lymphoma and Neurofibromatosis Type I and Literature Review. J Pediatr Hematol Oncol. 2021 05 01; 43(4):e535-e538.
-
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res. 2021 06 01; 27(11):3243-3252.
-
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. 2021 06; 39(3):829-835.
-
Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biol. 2020 08 26; 21(1):216.
-
Brain-wide structural and functional disruption in mice with oligodendrocyte-specific Nf1 deletion is rescued by inhibition of nitric oxide synthase. Proc Natl Acad Sci U S A. 2020 09 08; 117(36):22506-22513.
-
Integrated case-control and somatic-germline interaction analyses of soft-tissue sarcoma. J Med Genet. 2021 03; 58(3):145-153.
-
Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
-
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019 11 05; 29(6):1675-1689.e9.